Sirt5 Deacylation Activities Show Differential Sensitivities to Nicotinamide Inhibition

Frank Fischer1*, Melanie Gertz1*, Benjamin Suenkel1, Mahadevan Lakshminarasimhan1, Mike Schutkowski2, Clemens Steegborn1*

1 Department of Biochemistry and Research Center for Bio-Macromolecules, University of Bayreuth, Bayreuth, Germany, 2 Department of Enzymology, Institute for Biochemistry and Biotechnology, Martin Luther University Halle-Wittenberg, Halle, Germany

Abstract

Sirtuins are protein deacetylases regulating metabolism and aging processes, and the seven human isoforms are considered attractive therapeutic targets. Sirtuins transfer acyl groups from lysine sidechains to ADP-ribose, formed from the cosubstrate NAD+ by release of nicotinamide, which in turn is assumed to be a general Sirtuin inhibitor. Studies on Sirtuin regulation have been hampered, however, by shortcomings of available assays. Here, we describe a mass spectrometry–based, quantitative deacylation assay not requiring any substrate labeling. Using this assay, we show that the deacetylation activity of human Sirt5 features an unusual insensitivity to nicotinamide inhibition. In contrast, we find similar values for Sirt5 and Sirt3 for the intrinsic NAD+ affinity as well as the apparent NAD+ affinity in presence of peptide. Structure comparison and mutagenesis identify an Arg neighboring to the Sirt5 nicotinamide binding pocket as a mediator of nicotinamide resistance, and statistical sequence analyses along with testing further Sirtuins reveal a network of coevolved residues likely defining a nicotinamide-insensitive Sirtuin deacetylase family. The same Arg was recently reported to render Sirt5 a preferential desuccinylase, and we find that this Sirt5 activity is highly sensitive to nicotinamide inhibition. Analysis of Sirt5 structures and activity data suggest that an Arg/succinate interaction is the molecular basis of the differential nicotinamide sensitivities of the two Sirt5 activities. Our results thus indicate a Sirtuin subfamily with nicotinamide-insensitive deacetylase activity and suggest that the molecular features determining nicotinamide sensitivity overlap with those dominating deacylation specificity, possibly suggesting that other subfamily members might also prefer other acylations than acetylations.

Citation: Fischer F, Gertz M, Suenkel B, Lakshminarasimhan M, Schutkowski M, et al. (2012) Sirt5 Deacylation Activities Show Differential Sensitivities to Nicotinamide Inhibition. PLoS ONE 7(9): e45098. doi:10.1371/journal.pone.0045098

Editor: Peter Csermely, Semmelweis University, Hungary

Received July 24, 2012; Accepted August 13, 2012; Published September 19, 2012

Copyright: © 2012 Fischer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by Deutsche Forschungsgemeinschaft (STE1701/S to C.S.), BMBF (ProNet-T3 to M.S.), and elite network bavaria Graduate School “Lead structures of Cell Function” (M.L.). This publication was funded by the German Research Foundation and the University of Bayreuth in the funding programme Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: Clemens.Steegborn@uni-bayreuth.de

† These authors contributed equally to this work.

Introduction

Sirtuins are protein deacetylases that hydrolyze one NAD+ cosubstrate for each lysine sidechain they deacetylate, which links their activity to cellular energy levels [1,2]. They have been implicated in lifespan extending effects of caloric restriction and contribute to regulation of stress resistance, metabolism, and aging processes [1,3]. These physiological roles have stimulated intensive research into functions and substrates of Sirtuins, their physiological regulation, and small molecule drugs modulating their activity [3,4,5,6]. Mammals have seven isoforms, Sirt1 to Sirt7, with ical regulation, and small molecule drugs modulating their activity [1,3]. These physiological roles have stimulated intensive research into functions and substrates of Sirtuins, their physiological regulation, and small molecule drugs modulating their activity [3,4,5,6]. Mammals have seven isoforms, Sirt1 to Sirt7, with

phosphate synthetase 1 (CPS1). Sirt5-dependent deacetylation activates CPS1 and the urea cycle and increases during fasting, indicating that Sirt5 might contribute to caloric restriction effects [14,15]. Sirt5 was recently found to show higher lysine desuccinylase and demalonylation activity in vitro compared to its low deacetylation activity and it can desuccinylate CPS1 in vivo [16]. Studying the sofar unknown physiological functions of these acyl modifications and their Sirt5-dependent removal should help to improve our understanding of Sirt5 function. Sirt5 was also suggested to contribute to malignant diseases [17], but its pathophysiological role, targets, and regulation largely remain to be revealed [14].

Sirtuins share a common catalytic core topology, but with variations e.g. in the linker between Rossmann fold and Zn2+-binding domain [18]. The substrate polypeptide chain binds between these domains, next to NAD+. The acetyl oxygen reacts with C1’ of NAD+, yielding an ADP-ribosyl peptidyl imidate and nicotinamide. The reaction can then proceed to deacetylated lysine and 2'-O-acetyl-ADP-ribose, or, after rebinding of nicotinamide, reversal of the first step leads to substrate reformation and
apparent inhibition of deacylation [19,20]. NAD+ and nicotinamide are assumed to be general physiological Sirtuin regulators [21], but little is known about their regulatory effects on less studied Sirtuins, including several mammalian isoforms.

Studies on Sirtuin regulation have been hampered by shortcomings of the available substrates and activity assays [22,23]. The widely used “Fluor de Lys” (FdL) assay [24] and many other optical assays rely on peptides with a chemical label, which restricts them to a limited number of synthetic substrates and can cause artefacts such as the fluorophor-dependent activation of Sirt1 in the FdL assay [25,26]. Optical assays in general, including those employing non-modified substrates such as ELISAs [10], HPLC/UV [27], and coupled enzymatic assays [23], suffer from sensitivity to optical interference, e.g. from metabolites or pharmacological modulators. HPLC/UV assays thus require complete isolation of the quantified product [27], which often requires optimization for individual targets and prevents their application to complex mixtures, such as protein digests or lysates. Coupled assays are further sensitive to interferences with downstream reactions, and antibody-based methods are often not site specific. Many of these shortcomings can be overcome by using mass spectrometry-based assays, which were used, for example, in peptide experiments identifying consensus substrate sequences and for profiling endogenous deacylation activities [28]. Furthermore, mass spectrometry is increasingly used for studying acetylations of whole proteins, in particular in proteomics studies (see e.g. [29,30]). In principal, this approach enables label-free analysis, but stable isotope labeling is normally used for relative quantification [30,31].

Here, we describe a robust mass spectrometry deacylation assay based on direct and label-free relative quantification of substrate and product. Using the assay, we show that human Sirt5 deacylation activity exhibits an unusual insensitivity for inhibition by physiological nicotinamide concentrations. The enzyme’s desuccinylation activity, in contrast, is potently inhibited. Structure comparisons and mutagenesis reveal molecular features responsible for these effects, and evolutionary analyses suggest the existence of a Sirtuin family with a nicotinamide insensitive deacylation activity.

**Results and Discussion**

**A label-free quantitative deacylation assay using mass spectrometry**

Sirt5 tests in our lab with the FdL deacylation assay seemed to indicate an unusual insensitivity to nicotinamide inhibition, but data reliability was limited due to weak signals since the acetylated FdL-1 peptide is a bad Sirt5 substrate. Through peptide array experiments (unpublished data) we identified CPS1-Lys527 (FKRGLV(acK)GYGVKV) as a candidate for a better, and likely physiological, Sirt5 substrate site and we confirmed this result using an enzyme-coupled assay and binding studies (Fig. S1A). However, since the enzyme-coupled assay is based on nicotinamide consumption it can not be applied for studying Sirtuin inhibition by nicotinamide. To study effects of this compound and other substances not compatible with optical assays, we therefore established a robust and quantitative, mass spectrometry-based assay. Simultaneous measurement of substrate and product would enable the necessary normalization for run-to-run comparability, but that requires binding of both peptide species, acetylated and deacylated, to the chromatography column. Surprisingly, several acetylated and deacylated peptides tested did not bind to a C18 reversed phase column using standard LC-MS conditions, e.g. 0.1% formic acid, as loading buffer. A major influence of buffer and counter ions on peptide retention is well known, and we therefore tested more hydrophobic ones to increase in particular retention of the more hydrophilic deacylated peptides. Using 0.1% TFA and 0.02% HFBA turned out to be suitable for all tested peptides (data not shown). For accurate measurements of relative changes in acetylation without labeling, we then aimed at the parallel quantification of product and substrate. The novel Sirt5 substrate peptide CPS1-Lys527 was used for this systematic analysis. Calibration curves for acetylated and deacylated peptide revealed that substrate and product can be monitored accurately (Fig. 1A). Even though a slight but systematic under determination of the deacylated peptide occurs, normalization of the product with the remaining substrate allows relative quantification of acetylated and deacylated peptide and increases run-to-run comparability (Fig. 1B). The principle of our deacylation assay is schematically shown in Fig. 1C for the Sirtuin-dependent deacylation of a histone H3 acetylation site (H3-Lys116, IHK(acK)RV)T) as an example. The simple and robust assay is attractive for in vitro testing of compounds due to its insensitivity to many compound features disturbing other assays, and it can be applied for the monitoring of specific deacylation sites in substrates from synthesized peptides to whole proteins, even in complex mixtures.

**Human Sirt5 deacetylase activity shows an unusual insensitivity to nicotinamide inhibition**

We then used our mass spectrometry assay to analyze the effects of nicotinamide on Sirt5, and on other Sirtuins for comparison. To ensure that different deacylation activities, e.g. due to different efficiencies against different substrates or the presence of inhibitors, resulted in endpoint signals within the optimal measurement range, we adjusted reaction times and enzyme amounts using initial time series experiments. Applying the assay to the deacylation of a peptide based on an acetyl-CoA synthetase 2 acetylation site (ACS2-Lys642, TRSG(acK)VMR) by human Sirt3 in presence of increasing nicotinamide concentrations showed inhibition in the low micromolar range (IC50 = 43 ± 3 μM; Fig. 2A), similar to previous results on this and several other Sirtuins [12,13]. For deacylation of CPS1-Lys527 peptide by human Sirt5, we observed a much lower sensitivity to nicotinamide inhibition (IC50 = 1.6 ± 0.3 mM; Fig. 2A). Sirt5 thus is fully active in presence of up to ~100 μM nicotinamide, which is assumed to correspond to the higher end of cellular concentrations [21], whereas a major inhibitory effect requires non-physiological concentrations.

For other Sirtuins, a form of nicotinamide insensitivity was caused by a high ratio kforward to kreverse, leading to fast turnover of the ADP-ribosyl-peptidyl imidate and thereby preventing the nicotinamide-initiated reverse reaction of the intermediate [19]. In these cases, an incomplete loss of activity was observed at nicotinamide levels of 50 to 100 μM, and no further increase in inhibition at higher concentrations. No such initial drop in activity was observed in the Sirt3/nicotinamide dose-response. However, to test whether the substrate and its specific turnover rate influence the behavior of Sirt5, we analyzed inhibition of Sirt5 activity against ACS2-Lys642, which is deacylated slower by Sirt5 than CPS1-Lys527 (ACS2: 1.6 ± 0.1 nmol mg−1 min−1, CPS1: 4.1 ± 0.1 nmol mg−1 min−1; Fig. S1A). The Sirt5 affinity for CPS1 and ACS2 substrates was comparable (CPS1: Kd = 2.3 ± 1.5 μM, ACS2: Kd = 2.1 ± 0.7 μM; Fig. S1B), and also comparable to Sirt3’s affinity for the ACS2-Lys642 peptide (Kd = 2.4 ± 1.0 μM; Fig. S1B), showing that the difference in deacylation is due to different turnover. Nicotinamide inhibited Sirt3-dependent ACS2-Lys642 deacylation with an IC50 of
Nicotinamide inhibition of Sirt5 exhibits weak substrate dependence, but Sirt5 inhibition for both substrates is similar, compared to the order of magnitude stronger inhibition observed for the Sirt3/ACS2-Lys642 reaction. In fact, turnover by Sirt5 should be faster for physiological substrates than for the likely non-physiological ACS2-Lys642 site, so that in case of a negative correlation between turnover and nicotinamide sensitivity an even weaker inhibition than for ACS2-Lys642 would be expected. We thus conclude that nicotinamide inhibition of Sirt5-dependent deacetylation features weak substrate dependence but appears to generally require high, non-physiological nicotinamide concentrations.

Sirt5 has a typical Siruin NAD$^+$ affinity and is inhibited competitively by nicotinamide

Nicotinamide is the leaving group of the Siruin cosubstrate NAD$^+$. The low nicotinamide sensitivity of Sirt5 indicates that compared to other Siruins, differences in the nicotinamide subpocket of the NAD$^+$ binding site exist, which might also result in a lower NAD$^+$ affinity. However, determining NAD$^+$ affinities of Sirt3 and Sirt5 revealed an only slightly lower affinity for Sirt5 (Sirt3 $K_d$(NAD$^+$) = 0.71±0.23 mM; Sirt5 $K_d$(NAD$^+$) = 0.96±0.28 mM; Fig. 2B, Fig. S2A), not correlating with the order of magnitude difference in nicotinamide sensitivity. Similarly, $K_a$ values for NAD$^+$ under peptide saturation were comparable for Sirt3 (0.26±0.15 mM) and Sirt5 (0.20±0.07 mM; Fig. S2B). Thus, differences between Sirt5 and other Siruins in the NAD$^+$ binding site appear not to affect pocket features responsible for cosubstrate affinity but might be restricted to features determining details of nicotinamide rebinding (see below).

Nicotinamide-sensitive Siruins were shown to be inhibited non-competitively with respect to NAD$^+$ through a base exchange mechanism [19]. Consistently, NAD$^+$ affinities of Sirt3 and Sirt5 are not altered in presence of 0.5 mM nicotinamide (Sirt3 $K_d$(NAD$^+$) = 0.83±0.24 mM; Sirt5 $K_d$(NAD$^+$) = 0.92±0.23 mM; Fig. 2B, Fig. S2A), a concentration not affecting Sirt5 but completely inhibiting Sirt3. However, addition of increased nicotinamide concentrations that affect Sirt5 activity (5 mM and 10 mM, respectively) resulted in increased binding constants for NAD$^+$ to Sirt5 ($K_d$(NAD$^+$) = 1.44±0.28 mM at 5 mM nicotinamide; Fig. 2B, Fig. S2A), consistent with our findings, kinetic studies showed competitive binding of nicotinamide and NAD$^+$ to Siruin at nicotinamide concentrations above 2 mM [19]. We thus conclude that the surprising insensitivity of Sirt5 to physiological nicotinamide concentrations is due to a lack of non-competitive inhibition via base exchange, and that the inhibition observed at
very high nicotinamide concentrations is likely caused by competition with NAD⁺.

**Molecular features contributing to the nicotinamide resistance of Sirt5**

To identify molecular Sirt5 features responsible for its insensitivity to physiological nicotinamide levels, we compared its structure to other Sirtuins. For visualization of nicotinamide in the so-called C-pocket of the NAD⁺ binding cleft, we used the structure of a *Thermotoga maritima* Sir2 (Sir2Tm)/nicotinamide complex [20]. Overlaying this structure with human Sirt5 [32] and Sirt5 [33] revealed that the C-pockets are extremely similar but as a major difference close to the C-site we found Arg105, which corresponds to a Leu in the nicotinamide sensitive Sirt3 (Fig. 3A). Arg105 points toward the C-pocket and might interfere with the nicotinamide binding orientation required for the inhibitory base-exchange reaction. To identify additional candidate residues for rendering a nicotinamide binding site inhibition sensitive or insensitive, we searched for residues coevolved with Arg105 through statistical coupling analysis [34] of 932 aligned Sirtuin sequences. The amino acids in the five positions showing highest coupling to Arg105 (coupling scores >1.5; Fig. 3B) form a network of residues located within the nicotinamide binding site (Thr69, Tyr102; Fig. 3A) or adjacent to it (Trp77, Arg217, Trp222). To test the roles of these residues in nicotinamide sensitivity, we generated Sirt5 variants carrying at positions 105 and 69, respectively, the corresponding Sirt3 amino acid (Sirt5-Arg105Leu and Sirt5-Thr69Asp). Exchanging Thr69, which is located in the so called flexible cofactor binding loop, abolished Sirt5 activity. A Sirt5-Arg105Leu variant, however, retained wildtype deacetylation activity (wt: 2.1±0.4 nmol mg⁻¹ min⁻¹; Arg105Leu: 2.4±0.1 nmol mg⁻¹ min⁻¹) and partially gained Sirt3-like nicotinamide sensitivity (IC₅₀ = 189±23 μM; Fig. 3C). Thus, Arg105 appears to play a major role in rendering Sirt5 nicotinamide-insensitive, possibly assisted by coevolved residues.

Among the five phylogenetic Sirtuin classes [35], Sirt5 belongs to class III, which is considered evolutionary “old” and contains mostly bacterial members. Even though Arg105 and the coupled residues are not strictly conserved within this class, their variations match well with this classification (Fig. 3B). Consistently, we found nicotinamide sensitivities comparable to Sirt3 for the class I and class U members human Sirt1 (IC₅₀ = 62±4 μM), yeast Hst2 (IC₅₀ = 49±2 μM), and Sir2Tm (IC₅₀ = 39±5 μM; Fig. 3D, Fig. S3). In contrast, the class III Sirt5 ortholog from zebrafish (Sir5Zf), which features the identical amino acids as human Sirt5 in the Arg105-centered network, did not respond to physiological nicotinamide concentrations (IC₅₀ = 6.9±0.5 mM; Fig. 3D, Fig. S3). Furthermore, the bacterial class III member Sir2 from *Archeoglobus fulgidus* (Sir2Af2), which has an only slightly different residue pattern in the Arg105 network, also showed nicotinamide insensitivity (IC₅₀ = 2.1±0.15 mM; Fig. 3D, Fig. S3). In particular, the central Arg is replaced in Sir2Af2 by Met, which apparently also interferes with proper nicotinamide binding through its long sidechain (see below), showing that variations in the Arg105-centered motif occur in nicotinamide-insensitive Sirtuins. Although many members of the mainly prokaryotic class III Sirtuins would need to be tested for a firm conclusion, we speculate that besides a large group of nicotinamide sensitive Sirtuins, there might exist a family of Sirt5-like nicotinamide-insensitive Sirtuins, which likely corresponds to class III or a subfamily thereof.

**The nicotinamide-sensitivity of Sirt5 depends on the type of acyl group**

Recent publications showed an increased deacylation activity of Sirt5 for succinylated rather than acetylated Lys, at least partly due to lower KM values [16,36]. Interestingly, Du et al. identified similar residues as our study, Arg105 and the coupled residue Tyr102, to be important for the desuccinylase activity [16]. We therefore tested a succinylated version of the CPS1 peptide (CPS1-Lys527succ, benzoyl-RGVL(succK)EYGV-amide) as Sirt5 substrate in our mass spectrometry assay, and analyzed the sensitivity
of the reaction to nicotinamide inhibition. Consistent with published data [16], Sirt5 deacylated the succinylated peptide more efficiently than the acetylated one (Fig. 4A), although the difference was small in our assays due to the high substrate concentrations used (500 μM). Surprisingly, the desuccinylation reaction showed a nicotinamide sensitivity (IC50 = 2 μM; Fig. 4B) comparable to class I Sirtuins, revealing that Sirt5 deacetylation and desuccinylation activities are differently regulated by nicotinamide.

To investigate the molecular basis of the modification-dependent nicotinamide effect, we analyzed the structure of the available Sirt5/succinylated substrate/NAD+ complex [16]. As described [16], Arg105 contributes to substrate binding through an interaction with the succinyl carboxylate (Fig. 4C, rotamer 1). Without this interaction, the long Arg sidechain is likely to sample other conformations, as Arg adopts 33 conformations in proteins with comparable frequency [37]. Several Arg rotamers possible in absence of the succinate interaction, i.e. with acetylated substrates, point toward the nicotinamide binding pocket (see Fig. 4C, rotamer 2 for an example) and thus should interfere with proper nicotinamide binding for inhibition. To test this hypothesis, we analyzed deacylation reactions and nicotinamide effects using Sir2Af2, which has a Met replacing Arg105 (Met70). The Met cannot form a salt bridge to succinate - a Sirt5 Arg105Met variant indeed lost the desuccinylase activity [16] - but its long sidechain can point into the nicotinamide pocket. As expected, Sir2Af2 showed insignificant desuccinylation activity (KM and vmax not determinable) but pronounced deacetylase activity (KM = 220 ± 1 μM, vmax = 52 ± 6 nmol mg−1 min−1; kcat/KM = 132 s−1 M−1; Fig. 5A and Fig. S4A). Consistent with our

Figure 3. Structure comparison and identification of a Sirtuin sequence motive indicating nicotinamide insensitive deacetylation activity. (A) Structure comparison of Sirt3 (red) and Sirt5 (blue), overlaid with a Sir2Tm/nicotinamide complex (grey). Nicotinamide and coupled residues (see below) in Sirt3 and Sirt5 are displayed as sticks and colored by atom type for Sirt5 and for nicotinamide. (B) Statistical coupling analysis scores (lower panel) identify residues apparently coevolving (score cutoff used: 1.5) with Sirt5-Arg105: Thr69 and Tyr102 (highlighted in panel A), Trp77, Arg217, and Trp222. Amino acids in other Sirtuin sequences and the corresponding Sirtuin class are shown on top of the scores. (C) Inhibition Sirt5-Arg105Leu by nicotinamide. Activities, determined using our mass spectrometry assay, were normalized against activity in absence of nicotinamide. Data for wildtype Sirt3 and Sirt5 from Fig. 2A are shown here for comparison. (D) Comparison of IC50 values, determined using the mass spectrometry assay, for nicotinamide inhibition of class I and III Sirtuins and of the Sirt5-Arg105Leu variant. Error bars represent the standard error of the fit. NAM, nicotinamide.

doi:10.1371/journal.pone.0045098.g003
Figure 4. Nicotinamide effects on Sirt5 activity depend on the type of acyl group. (A) Comparison of Sirt5 activities against acetylated and succinylated CPS1-Lys527 peptide, determined by mass spectrometry and normalized using the desuccinylation activity. Error bars represent standard errors of linear fits to time-series experiments. (B) Nicotinamide-dependent inhibition of Sirt5 activity against acetylated and succinylated CPS1-Lys527 peptide, determined using mass spectrometry and normalized against activity in absence of nicotinamide. The Sirt3/ACS2 and Sirt5/ CPS1 curves from Fig. 2A were added for comparison. (C) Cartoon representation of the Sirt5/succinylated substrate/NAD+ complex structure. The ligands and Arg105 are shown as sticks colored according to atom type (ligands) or in blue (Arg105). A modeled alternative sidechain conformation CPS1-Lys527 peptide, determined using mass spectrometry and normalized against activity in absence of nicotinamide. The Sirt3/ACS2 and Sirt5/ CPS1 succ, succinylated CPS1-Lys527 peptide; NAM, nicotinamide.
doi:10.1371/journal.pone.0045098.g004

Conclusions and outlook

Our mass spectrometry-based assay allows robust and label-free monitoring of deacylation reactions, such as deacetylation and desuccinylation. The obtained activity data suggest that a Sirtuin subfamily exists whose deacylation activity shows no sensitivity to inhibition by physiological nicotinamide concentrations, and that the conformational freedom of the residue corresponding to Arg105 in human Sirt5 has a major influence on nicotinamide sensitivity. In Sirt5, this residue is conformationally restrained when interacting with the enzyme’s preferred substrate acylation, a malonyl or succinyl group, likely causing the increased sensitivity of the Sirt5 desuccinylation activity to nicotinamide inhibition. At present, one cannot exclude the possibility that both activities, deacetylation and desuccinylation, contribute to Sirt5 function, since the more efficient in vitro activity desuccinylation can be lowered in vivo by nicotinamide, and no quantitative information is available whether acetylated or succinylated Sirt5 substrate sites dominate in vivo. However, it is tempting to speculate that a low nicotinamide deacylation sensitivity generally indicates that the identified residue lacks its optimal acyl interaction partner and thus, that a side-activity rather than the major deacylation activity is measured. If this speculation turns out to be true, it will be interesting to see which acylations constitute the physiological substrates for Sir2A2 and the Sirtuin subfamily whose deacylation activity shows low nicotinamide sensitivity.

Sirtuins are attractive drug targets [3,4,5] and many modulators have been identified through screening methods or rational approaches [4,6,38], but most compounds show low potency and/or specificity and no suitable compounds are available for Sirt5. The unique Sirt5 deacetylation activity [16] and nicotinamide sensitivity pattern (this work) now indicate a promising approach for drug development: Exploiting the isoform-specific features around the nicotinamide binding pocket investigated here should allow the development of small molecule inhibitors selective for Sirt5 [39], which would be leads for pharmacological drug development and excellent tools for functional studies on Sirt5.

Methods

Chemicals

Chemicals were obtained from Sigma (Saint Louis, USA) if not stated differently. Acetylated peptides and succinylated Prx1-Lys197 peptide were from GL Biochem (Shanghai, PRC). Succinylated CPS1 peptide was synthesized as benzoylated amide using rink amide MBHA resin and standard Fmoc solid phase synthesis (20% piperidine in DMF for deprotection and PyBOP/ DIPEA for couplings). After treatment with 96% TFA, the peptide was precipitated with diethylether, purified by C18 HPLC, and succinylated using succinic anhydride in DMF in presence of DIPEA, followed by NaOH treatment to remove tyrosine succinylations. Succinylated peptide was purified by C18 HPLC, and purity and identity analyzed using LC-ESI-MS.
Recombinant expression and purification of human Sirt1, Sirt3, and Sirt5, zebrafish Sirt5, yeast Hst2, A. fulgidus Sir2Af2, and T. maritima Sir2Tm

Proteins were expressed and purified using standard methods described in detail in Methods S1. Briefly, gene fragments were cloned into pET15b (Sirt1; Novagen, Darmstadt, Germany) or pET151/D-Topo (Invitrogen, Carlsbad, USA) and expressed in *E. coli* BL21DE3 (Hst2) or *E. coli* BL21DE3Rosetta2 (all other proteins). Proteins were purified using Talon (Clontech, Mountain View, USA) affinity chromatography followed by gel filtration on a Superdex 200 (Sirt1) or Superose12 column (all other proteins) (GE Healthcare, Waukesha, USA). Sirt1 was further purified by HiTrapQHP (GE Healthcare) ion exchange chromatography. Expression constructs for Sir2Af2 and Sir2Tm [20,40] were provided by the Wolberger lab via Addgene (Cambridge, USA) and proteins produced according to [41].

Coupled deacetylation assay

Coupled deacetylation assays were performed as described [23]. Briefly, reaction mixtures were supplemented with 10 µM Sirt3, 0.5 mM peptide, and 2.5 mM NAD⁺ and the decrease in absorbance at 340 nm was monitored over 1 h at room temperature. Controls were done without Sirt5 and all assays were repeated at least twice (results shown are representatives).

MS-based peptide deacylation assay

Reaction mixtures contained 20 mM Tris/HCl pH 7.8, 150 mM NaCl, 2.5 mM NAD⁺, 0.5 mM substrate peptide, and varying concentrations of nicotinamide and Sirtuin protein if not stated differently. Deacetylase activities were started by adding peptide and stopped with TFA (0.25% final concentration) after 10 to 60 min incubation at 37°C. Samples were diluted with 0.1% formic acid and filtered using 10 kDa cutoff concentrators. Samples were analyzed on an LC-ESI-MS system consisting of a Prominence HPLC (Shimadzu, Duisburg, Germany) with Sil20AC autosampler connected to an LTQ XL mass spectrometer (Thermo Fisher, Bremen, Germany). 1 pmol peptide was injected and species separated using a linear gradient from 0% to 45% buffer B within 30 min (buffer A: 0.1% TFA, 0.02% HFBA; buffer B: 70% ACN, 0.1% TFA, 0.02% HFBA) and a fritless 100 µm ID capillary reversed phase column (Reprosil C18 AQ, 3 µm; Dr. Maisch, Germany) with a flow rate of 250 nL/min. Full MS scans between 375 and 1600 m/z, followed by full MS/MS scans for the three most intensively ions were acquired using Xcalibur 2.1 software. Extracted ion chromatograms (XICs) with mass windows of ±2 m/z were generated for the acylated and deacylated peptide, and peak areas were determined using automatic peak area detection of the Xcalibur Qual Browser module and further analyzed with Excel (Microsoft, Seattle, USA) or GraFit (Erithacus

Figure 5. Role of Sir2Af2-Met70 in deacylation specificity and nicotinamide sensitivity. (A) Substrate concentration dependent activity of Sir2Af2 against acetylated (●) and succinylated (△) Prx1-Lys197 peptides determined using the mass spectrometry assay. Error bars represent standard errors of linear fits to time-series measurements. (B) Comparison of Sir2Af2 activities against acetylated and succinylated Prx1-Lys197 peptide, determined using mass spectrometry and normalized against wt deacetylation activity. Error bars represent standard errors of linear fits to time-series experiments. (C+D) Nicotinamide-dependent inhibition of Sir2Af2 wt (●) and Met70Arg variant (○) activity against (C) succinylated and (D) acetylated Prx1-Lys197 peptide, determined using mass spectrometry and normalized against activity in absence of nicotinamide. The effect of exchanging Met70 to Arg is indicated by arrows. Prx1succ, succinylated Prx1-Lys197 peptide; NAM, nicotinamide.

doi:10.1371/journal.pone.0045098.g005
Software, West Sussex, UK). MS raw data for all figures are assembled in Table S1.

Binding analysis by microscale thermophoresis

For labeling, 100 μM Sirtuin were incubated with 200 μM fluorescein isothiocyanate (Thermo Fisher) in 20 mM HEPES pH 7.5, 150 mM NaCl overnight at 4°C in the dark. Non-bound dye was removed using a Nap25 column (GE Healthcare). Dissociation constants were determined from microscale thermophoresis [42] using a Monolith NT.115 (NanoTemper Technologies, Munich, Germany). Ligand was titrated to 100 nM labeled Sirtuin in presence or absence of nicotinamide (0.5/5/10 mM) or substrate peptide (25 μM), mixtures preincubated for 30 min at room temperature, and thermophoresis measured with an excitation wavelength of 470 nm, emission wavelength 520 nm, LED-power 20–50%, and laser-power 40%. Dissociation constants were determined by non-linear fitting in GraFit.

Statistical coupling analysis

Covariation of residues was calculated using the method and software of Lockless et al. [34] and an alignment of human Sirt5 with 932 Sirtuin sequences of the PFAM database (http://www.sanger.ac.uk/resources/databases/pfam.html) manually edited in Genedoc [43].

Structure analysis

The alternative rotamer of Arg105 in the Sirt5/succinylated peptide/NAD\(^+\) complex (PDB ID 3RIY, [16]) and the structure overlay of human Sirt3 (3GLS [32], human Sirt5 (2NYR [33]), and T. marinae Sirt2/M (1YC5 [20]) were generated using Coot [44]. Structure images were prepared using PyMol (Delano Sci. LLC, http://www.pymol.org).

Supporting Information

Figure S1 Improved Sirt5 substrates and their binding to Sirt5.

(PDF)

Figure S2 Microscale thermophoresis experiments for determination of dissociation constants for NAD\(^+\) binding to human Sirt3 and Sirt5.

(PDF)

Figure S3 Nicotinamide (NAM) dose response curves for various Sirtuins.

(PDF)

Figure S4

Methods S1

Table S1 Mass spectrometry raw data for Figures 1–5.

(XLSX)

References

1. Guarente L, Picard F (2005) Calorie restriction - the SIR2 connection. Cell 120: 473–482.
2. Sauve AA, Wolberger C, Schramm VL, Boeke JD (2006) The biochemistry of sirtuins. Annu Rev Biochem 75: 433–463.
3. Milor JC, Dena JM (2000) The Sirtuin family: therapeutic targets to treat diseases of aging.Curr Opin Chem Biol 12: 11–17.
4. Haigis MC, Sinclair DA (2010) Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5: 253–295.
5. Lakshminarasimhan M, Steegborn C (2011) Emerging mitochondrial signaling mechanisms in physiology, aging processes, and as drug targets. Exp Gerontol 46: 174–177.
6. Schlicker C, Boanca G, Lakshminarasimhan M, Steegborn C (2011) Structure-based development of novel sirtuin inhibitors. Aging (Albany NY) 3: 852-872.
7. Michan S, Sinclair D (2007) Sirtuins in mammals: insights into their biological function. Biochem J 404: 1–13.
8. Shi T, Wang F, Stieren E, Tong Q (2005) SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem 280: 13560–13567.
9. Ahn BH, Kim HS, Song S, Lee IH, Liu J, et al. (2008) A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci USA 105: 14447–14452.
10. Schlicker C, Gertz M, Papahodeou P, Kachholz B, Becker CF, et al. (2008) Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt5 and Sirt6. J Mol Biol 382: 790–801.
11. North BJ, Sinclair DA (2007) Sirtuins: a conserved key unlocking AceCS activity. Trends Biochem Sci 32: 1–4.
12. Sauve AA (2010) Sirtuin chemical mechanisms. Biochim Biophys Acta 1804: 1591–1603.
13. Jin L, Galonek H, Israeli D, Gharib M, Morrison M, et al. (2009) Biochemical characterization, localization, and tissue distribution of the longer form of mouse SIRT3. Protein Sci 18: 514–525.
14. Gertz M, Steegborn C (2010) Function and regulation of the mitochondrial Sirtuin isoform Sirt5 in Mammalia. Biochim Biophys Acta 1804: 1658–1665.
15. Nakagawa T, Lomb DJ, Haigis MC, Guarente L (2009) SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 137: 560–570.

Acknowledgments

We thank Dr. Steve Lockless (Texas A&M University) for providing statistical coupling calculation software, Giang Nguyen and Felix Hsuilk for help with protein preparation, and Norbert Grüllnebeck and Edith Gutmann for technical assistance.

Author Contributions

Conceived and designed the experiments: FF MG CS. Performed the experiments: FF MG BS ML MS. Analyzed the data: FF MG BS. Contributed reagents/materials/analysis tools: CS MS. Wrote the paper: FF MG CS.
29. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, et al. (2006) Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23: 607–618.
30. Choudhary C, Kumar C, Gnäd F, Nielsen ML, Rehman M, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834–840.
31. Morselli E, Marino G, Bennetzen MV, Eisenberg T, Megalou E, et al. (2011) Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J Cell Biol 192: 615–629.
32. Jin L, Wei W, Jiang Y, Peng H, Cai J, et al. (2009) Crystal structures of human SIRT3 displaying substrate-induced conformational changes. J Biol Chem 284: 24394–24403.
33. Schuetz A, Min J, Antoshenko T, Wang CL, Allali-Hassani A, et al. (2007) Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin. Structure 15: 377–389.
34. Lockless SW, Ranganathan R (1999) Evolutionarily conserved pathways of energetic connectivity in protein families. Science 286: 295–299.
35. Frye RA (2000) Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 273: 793–798.
36. Peng C, Lu Z, Xie Z, Cheng Z, Chen Y, et al. (2011) The first identification of lysine malonylation substrates and its regulatory enzyme. Mol Cell Proteomics 10: M111 012658.
37. Laskowski RA, Rullmann JA, MacArthur MW, Kaptein R, Thornton JM (1996) AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 8: 477–486.
38. Cen Y (2010) Sir2 inhibitors: The approach to affinity and selectivity. Biochim Biophys Acta 1804: 1635–1644.
39. He B, Da J, Liu H (2012) Thioisocyanyl peptides as Sirt5-specific inhibitors. J Am Chem Soc 134: 1922–1925.
40. Avalos JL, Celic I, Muhammad S, Cougrov M, Boeke JD, et al. (2002) Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol Cell 10: 523–535.
41. Smith JS, Avalos J, Celic I, Muhammad S, Wolberger C, et al. (2002) SIR2 family of NAD(+) dependent protein deacetylases. Methods Enzymol 353: 282–300.
42. Wierken CJ, Baake P, Rothbauer U, Braun D, Duh S (2010) Protein-binding assays in biological liquids using microscale thermophoresis. Nat Commun 1: 100.
43. Nicholas KB Jr, Nicholas HB, Deerfield DWI (1997) GeneDoc: Analysis and Visualization of Genetic Variation. EMBOEWEWINE 4: 14.
44. Emsley P, Cowtan K (2004) Coot: Model-Building Tools for Molecular Graphics. Acta Cryst Section D 60: 2126–2132.